vplab™ nutrition ultra men’s sport (paziņots 2014.) cits, kaplete
vp laboratory, ltd. - cits, kaplete
vplab™ nutrition ultra women’s (paziņots 2013.) cits, kaplete
vp laboratory, ltd. - cits, kaplete
polivy
roche registration gmbh - polatuzumab vedotin - limfomas b-Šūnu - antineoplastiski līdzekļi - polivy kopā ar bendamustine un rituksimabs ir norādīts ārstēšanai pieaugušiem pacientiem ar relapsed/ugunsizturīgi difūza liela b-šūnu limfoma (dlbcl), kas nav kandidātu hematopoētisko cilmes šūnu transplantācijas. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
fludeoxyglucose (18f) karolinska 450-11250 mbq/ml šķīdums injekcijām
karolinska university hospital, sweden - fludezoksiglikoze (18f) - Šķīdums injekcijām - 450-11250 mbq/ml
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiski līdzekļi - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastiski līdzekļi - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
kantik®
adama - emulsijas koncentrāts - fenpropidīns + prohlorazs + tebukonazols - fungicīdi